The corneal melting point

Academic Unit of Clinical Experimental Sciences, Faculty of Medicine, Eye Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
Eye (London, England) (Impact Factor: 2.08). 07/2012; 26(8):1029-30. DOI: 10.1038/eye.2012.136
Source: PubMed
14 Reads
  • Source
    • "Topical nonsteroidal antiinflammatory drugs may also inhibit the healing process and should be avoided.29 In the event of stromal melting, use of topical collagenase inhibitors, such as N-acetylcysteine, and systemic administration of tetracycline or medroxyprogesterone may be considered.30–32 Use of topical antibiotic eye drops to prevent infection in eyes with NK at stages 2 and 3 is recommended. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurotrophic keratitis (NK) is a degenerative disease characterized by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. Several causes of NK, including herpetic keratitis, diabetes, and ophthalmic and neurosurgical procedures, share the common mechanism of trigeminal damage. Diagnosis of NK requires accurate investigation of clinical ocular and systemic history, complete eye examination, and assessment of corneal sensitivity. All diagnostic procedures to achieve correct diagnosis and classification of NK, including additional examinations such as in vivo confocal microscopy, are reviewed. NK can be classified according to severity of corneal damage, ie, epithelial alterations (stage 1), persistent epithelial defect (stage 2), and corneal ulcer (stage 3). Management of NK should be based on clinical severity, and aimed at promoting corneal healing and preventing progression of the disease to stromal melting and perforation. Concomitant ocular diseases, such as exposure keratitis, dry eye, and limbal stem cell deficiency, negatively influence the outcome of NK and should be treated. Currently, no specific medical treatment exists, and surgical approaches, such as amniotic membrane transplantation and conjunctival flap, are effective in preserving eye integrity, without ameliorating corneal sensitivity or visual function. This review describes experimental and clinical reports showing several novel and potential therapies for NK, including growth factors and metalloprotease inhibitors, as well as three ongoing Phase II clinical trials.
    Full-text · Article · Mar 2014 · Clinical ophthalmology (Auckland, N.Z.)